153 related articles for article (PubMed ID: 19083253)
1. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
Brunel-Guitton C; Rivard GE; Galipeau J; Alos N; Miron MC; Therrien R; Mitchell G; Lapierre G; Lambert M
Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253
[TBL] [Abstract][Full Text] [Related]
2. Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience.
Gumus E; Karhan AN; Hizarcioglu-Gulsen H; Demir H; Ozen H; Saltik Temizel IN; Dokmeci Emre S; Yuce A
Eur J Med Genet; 2021 Nov; 64(11):104339. PubMed ID: 34500086
[TBL] [Abstract][Full Text] [Related]
3. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
4. [Clinical outcomes of 2 pediatric patients with Gaucher's disease in enzyme replacement therapy for 9 years].
Quijada Fraile P; Martín Hernández E; Teresa García-Silva M
Med Clin (Barc); 2011 Sep; 137 Suppl 1():43-5. PubMed ID: 22230125
[TBL] [Abstract][Full Text] [Related]
5. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
[TBL] [Abstract][Full Text] [Related]
6. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
7. Divergent phenotypes in Gaucher disease implicate the role of modifiers.
Goker-Alpan O; Hruska KS; Orvisky E; Kishnani PS; Stubblefield BK; Schiffmann R; Sidransky E
J Med Genet; 2005 Jun; 42(6):e37. PubMed ID: 15937077
[TBL] [Abstract][Full Text] [Related]
8. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
El-Beshlawy A; Ragab L; Youssry I; Yakout K; El-Kiki H; Eid K; Mansour IM; Abd El-Hamid S; Yang M; Mistry PK
J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874
[TBL] [Abstract][Full Text] [Related]
10. Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.
Choy FY; Zhang W; Shi HP; Zay A; Campbell T; Tang N; Ferreira P
Blood Cells Mol Dis; 2007; 38(3):287-93. PubMed ID: 17196853
[TBL] [Abstract][Full Text] [Related]
11. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
Grigorescu-Sido P; Drugan C; Alkhzouz C; Zimmermann A; Coldea C; Denes C; Grigorescu MD; Cret V; Bucerzan S
Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
[TBL] [Abstract][Full Text] [Related]
12. Gaucher disease: studies of phenotype, molecular diagnosis and treatment.
Rice EO; Mifflin TE; Sakallah S; Lee RE; Sansieri CA; Barranger JA
Clin Genet; 1996 Mar; 49(3):111-8. PubMed ID: 8737974
[TBL] [Abstract][Full Text] [Related]
13. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight.
Ucar SK; Coker M; Argin M; Akman S; Kara S; Simsek DG; Darcan S
Mol Genet Metab; 2009 Jan; 96(1):50-1. PubMed ID: 19006678
[TBL] [Abstract][Full Text] [Related]
14. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
[TBL] [Abstract][Full Text] [Related]
15. Cessation of enzyme replacement therapy in Gaucher disease.
Grinzaid KA; Geller E; Hanna SL; Elsas LJ
Genet Med; 2002; 4(6):427-33. PubMed ID: 12509713
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia.
Chan LL; Lin HP
Med J Malaysia; 2002 Sep; 57(3):348-52. PubMed ID: 12440275
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease.
Arıkan-Ayyıldız Z; Yuce A; Uslu-Kızılkan N; Demir H; Gurakan F
Pediatr Blood Cancer; 2011 Apr; 56(4):664-6. PubMed ID: 21298757
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
[TBL] [Abstract][Full Text] [Related]
19. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
20. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.
Davies EH; Erikson A; Collin-Histed T; Mengel E; Tylki-Szymanska A; Vellodi A
J Inherit Metab Dis; 2007 Nov; 30(6):935-42. PubMed ID: 17994286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
